

Review

Genomic approaches to research in pulmonary hypertension

Mark W Geraci*, Bifeng Gao*, Yasushi Hoshikawa*, Michael E Yeager*, Rubin M Tuder† and Norbert F Voelkel*

*Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA

†Department of Pathology, Johns Hopkins University, School of Medicine, USA

Correspondence: Mark W Geraci, MD, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Campus Box C-272, 4200 East Ninth Avenue, Denver, CO 80262, USA. Tel: +1 303 315 7047; fax: +1 303 315 5632; e-mail: mark.geraci@uchsc.edu

Received: 16 February 2001

Revisions requested: 13 March 2001

Revisions received: 22 March 2001

Accepted: 3 April 2001

Published: 1 May 2001

Respir Res 2001, **2**:210–215

© 2001 BioMed Central Ltd
(Print ISSN 1465-9921; Online ISSN 1465-993X)

Abstract

Genomics, or the study of genes and their function, is a burgeoning field with many new technologies. In the present review, we explore the application of genomic approaches to the study of pulmonary hypertension (PH). Candidate genes, important to the pathobiology of the disease, have been investigated. Rodent models enable the manipulation of selected genes, either by transgenesis or targeted disruption. Mutational analysis of genes in the transforming growth factor- β family have proven pivotal in both familial and sporadic forms of primary PH. Finally, microarray gene expression analysis is a robust molecular tool to aid in delineating the pathobiology of this disease.

Keywords: genetic mutation, knockout mouse, microarray, pulmonary hypertension, transgenic mouse

Introduction

Pulmonary hypertension (PH) refers to a spectrum of diseases where the pulmonary artery pressure is elevated. A new classification of PH has recently been proposed [1]. No cause can be elucidated in primary (or sporadic, idiopathic) pulmonary hypertension (PPH). Secondary forms of PH can occur in association with congenital heart disease, thromboembolic disease, HIV, anorexigen usage, and a variety of connective tissue disorders. Familial primary pulmonary hypertension (FPPH) has been associated with heterozygous germline mutations in the bone morphogenetic protein type II receptor gene (BMPR2) [2,3]. While this recent discovery has generated extreme interest, the pathobiology of severe PH remains enigmatic. Recent genomic approaches to investigate PH are reviewed. Early studies investigated the alterations of

vasoactive and growth factor related genes. Animal models, using either pharmaceutical approaches, transgenics, or targeted disruption of genes, have allowed for whole animal modeling of specific pathways in the development of PH. Progress in medical genetic investigations has led to the discovery of a gene (BMPR2) associated with FPPH. Finally, microarray expression analysis has been utilized to investigate animal models, and has shown to be a useful tool providing novel information and better characterization of the molecular pathobiology of distinct clinical phenotypes of PH.

Genes involved in the pathobiology of PH

Most investigations of the role of specific genes in the pathobiology of PH have focused either on the balance of vasoconstriction and vasodilation or on specific growth

BMPR2 = bone morphogenetic protein type II receptor gene; eNOS = endothelial nitric oxide synthase; FPPH = familial primary pulmonary hypertension; PGI₂ = prostacyclin; PGIS = prostacyclin synthase; PH = pulmonary hypertension; PPAR = peroxisome proliferator-activated receptor; PPH = primary pulmonary hypertension; Tg+, Tg- = transgenic, nontransgenic littermate; TGF- β = transforming growth factor- β .

factors, inflammatory mediators, or ion channels. Another approach has been to compartmentalize the vasculature, and focus the investigations on the endothelium, smooth muscle cells, and the adventitia/extracellular matrix. Christman *et al* initially reported an imbalance of prostacyclin (PGI₂) and thromboxane metabolites in the urine of patients with both primary and secondary forms of PH, with more vasoconstrictor thromboxane metabolites in patients with PH [4]. Giaid *et al* similarly studied the expression of endothelin-1 in the lungs of patients with PH, and showed increased expression by both *in situ* hybridization and immunohistochemistry [5]. Overexpression of 5-lipoxygenase and 5-lipoxygenase activating protein was shown in endothelial cells of plexiform lesions and inflammatory cells in patients with PPH, suggesting that overexpression of enzymes involved in generation of inflammatory mediators may play a role in the pathogenesis of PPH [6]. As there is an imbalance of PGI₂ and thromboxane, we wondered whether PPH patients had diminished synthetic enzyme for PGI₂. We demonstrated, by *in situ* hybridization, western analysis and immunohistochemistry, that patients with PPH have decreased lung tissue prostacyclin synthase (PGIS) [7]. A comprehensive histochemical analysis of plexiform lesions was performed by Cool *et al* [8]. This analysis showed that the endothelial cells of plexiform lesions express, intensely and uniformly, the vascular endothelial growth factor receptor KDR. The analysis by Cool *et al* also showed that the cells segregate phenotypically into cyclin-kinase inhibitor p27/kip1-negative cells in the central core of the plexiform lesion and p27/kip1-positive cells in peripheral areas adjacent to incipient blood vessel formation. Using immunohistochemistry and three-dimensional reconstruction techniques, the plexiform lesions were shown to be dynamic vascular structures characterized by at least two endothelial cell phenotypes. Despite these powerful investigations, a unifying pathobiological scheme has remained elusive.

Animal models of PH

Commonly utilized models of PH in animals are the chronic hypoxic model and the monocrotaline model. Interestingly, monocrotaline causes PH in the rat, but not the mouse. Exactly how closely the animal models recapitulate human disease remains a source of debate. These two models have, however, been useful for hypothesis testing and determining the response of genetically altered animals. Several specific genes have been targeted for investigation in rodent models.

5-Lipoxygenase

Mice with targeted disruption of 5-lipoxygenase were subjected to chronic hypoxia [9]. These mice developed less right ventricular hypertrophy than matched controls, supporting the hypothesis that 5-lipoxygenase is involved in pulmonary vascular tone in rodent hypoxia models.

Nitric oxide synthase

Targeted disruption of the endothelial nitric oxide synthase (eNOS) gene results in mice with increased susceptibility to hypoxic-induced PH [10]. These studies conclude that eNOS-derived nitric oxide is an important modulator of the pulmonary vascular response to chronic hypoxia, and more than 50% of eNOS expression is required to maintain normal pulmonary vascular tone [10].

PGIS and prostacyclin receptor

We hypothesized that selective pulmonary overexpression of PGIS may prevent the development of PH. Transgenic mice were created with selective pulmonary PGIS overexpression using a construct of the 3.7 kb human surfactant protein-C promoter and the rat PGIS cDNA. Transgenic mice (Tg+) and nontransgenic littermates (Tg-) were subjected to a simulated altitude of 17,000 feet for 5 weeks. After exposure to chronic hypobaric hypoxia, Tg+ mice have lower right ventricular systolic pressure than do Tg- mice. Histologic examination of the lungs revealed nearly normal arteriolar vessels in the Tg+ mice in comparison with vessel wall hypertrophy in the Tg- mice. The Tg+ mice were thus protected from the development of PH after exposure to chronic hypobaric hypoxia. We conclude that PGIS plays a major role in modifying the pulmonary vascular response to chronic hypoxia. Additional data investigating the prostacyclin receptor knockout mice support the important modulating role of PGI₂ since chronic hypoxic PH is more severe in these prostacyclin receptor knockout mice when compared with the wild-type animals [11]. This has important implications for the pathogenesis and treatment of severe PH [12].

Matrix metalloproteinase and serine elastase

Important changes occur in PH in the vascular adventitia, with increased production of the extracellular matrix. Matrix metalloproteinases can stimulate the production of mitogenic co-factors, such as tenascin. Cowan *et al* recently showed that direct inhibition of serine elastases led to complete regression of pathological changes in experimental PH caused by monocrotaline [13].

Vascular endothelial growth factor

In contrast to the human disease, classical rodent models of hypoxia and monocrotaline lack the clustered proliferation of endothelial cells. Taraseviciene-Stewart *et al* recently showed that chronic administration of a vascular endothelial growth factor-2 inhibitor in chronically hypoxic rats lead, first, to endothelial cell death, then to obliteration of the vessel lumen by proliferating endothelial cells and, finally, to PH [14]. A broad spectrum caspase inhibitor blocked this proliferation. This model more accurately depicts the cellular events seen in the human condition.

Gene transfer

The promise of gene transfer therapy remains the 'Holy Grail' for many genetic diseases as well as diseases that exhibit a specific enzyme deficiency. PH is no exception. Adenoviral gene transfer has been used in rats to show diminished response to acute hypoxia. This has been accomplished by transfer of eNOS [15] and by gene therapy with PGIS [16]. Long-term benefit in chronic hypoxia has not been reported. Repeated adenoviral PGIS transfection has shown some effectiveness in decreasing PH in rats using the monocrotaline model [17].

Microarray expression analysis of animal models

We performed microarray analysis of our PGIS Tg+ animals to determine the global changes in gene expression caused by PGIS overexpression. Transgene negative littermates were examined as controls. The mRNA from five transgenic mouse lungs was pooled and compared with five nontransgenic, sex-matched littermates. Using strict criteria (a twofold change in expression), we determined that a definable number of genes was differentially expressed between the lungs of transgenic and nontransgenic animals. Of the 6500 genes surveyed, 32 genes showed an increase in expression and 26 showed a decrease in expression. Table 1 presents genes that demonstrate the most significant changes in expression (at least a 2.2-fold change) when comparing the lung mRNA from transgenic and nontransgenic mice.

Array analysis importantly demonstrated changes in both peroxisome proliferator-activated receptor (PPAR) λ and PPAR δ , and we have followed up these studies with work demonstrating that prostacyclin activates PPAR δ in colorectal cancer [18]. Histochemical analysis in human colorectal tumors demonstrated colocalization of PPAR δ and cyclooxygenase-2. An experimental condition was created in which PGI₂ production could be correlated with PPAR δ transcriptional activity. Transient transfection assays established that endogenously synthesized PGI₂ could serve as a ligand for PPAR δ . A stable PGI₂ analog also induces transactivation of PPAR δ in human colon cancer cells, demonstrating that endogenous PPAR δ is transcriptionally responsive to PGI₂ [18].

Human medical genetics

FPPH is an autosomal dominant disorder that is indistinguishable from sporadic PPH. The disease has reduced penetrance, and over 90% of patients have no known family history of the disease [19]. Linkage analysis in affected families enabled the locus to be defined within a 3 cM region of chromosome 2q33. Using a positional candidate-gene strategy, two groups were subsequently able to independently confirm that heterozygous germline mutations in BMPR2 cause FPPH [2,3]. Using a high-throughput denaturing high-performance liquid chromatography

Table 1

Genes demonstrating the most significant changes in expression

Genes with significantly increased expression	Genes with significantly decreased expression
PPAR γ	PPAR δ
RAS GTPase	Cyclooxygenase-2
Focal adhesion kinase	Multidrug resistance protein
Keratinocyte growth factor receptor	α -Catenin
Epidermal growth factor	TGF- β and TGF- β receptor
IL-7 and IL-17 receptors	Wilm's tumor gene
Cathepsins C, D, and E	BCR-abl


PPAR, Peroxisome proliferator-activated receptor; TGF, transforming growth factor.

approach [20] has enabled the rapid identification of numerous mutations responsible for haploinsufficiency of BMPR2 [2]. Furthermore, germline mutations of BMPR2 have also been identified in ~26% of sporadic cases of PPH [21]. 'Sporadic' cases sometimes actually represented occult familial cases of PPH [21]. The molecular spectrum of BMPR2 mutations is more fully elucidated in an analysis of 47 European families [22]. The majority of mutations (58%) are predicted to lead to premature termination codons. However, mutations in BMPR2 have not been found in 45% of families with PPH [22]. A number of possible explanations for this fact are possible, including mutations in intronic and 3'-untranslated regions that are heretofore not examined, rearrangements in the transcribed gene that may occur, or genetic heterogeneity perhaps playing a role.

BMPR2 encodes a type II receptor member of the transforming growth factor- β (TGF- β) superfamily. Type II receptors, which have serine/threonine kinase activity, act as cell-signaling molecules. Following ligand binding, type II receptors form heteromeric complexes with membrane-bound type I receptors. This initiates phosphorylation of the type I receptor and downstream intracellular Smads [23]. This pathway is diverse and the specificity in cell growth and differentiation appears to be mediated through transcriptional control. The importance of the TGF- β pathway in vascular disorders is evidenced by the fact that two other components of this pathway, endoglin and the activin receptor-like kinase-1 gene, are mutated in hereditary hemorrhagic telangiectasia [24,25].

Mutational analysis

Lee *et al* [26] recently demonstrated that the endothelial cells within plexiform lesions of patients with PPH expand in a monoclonal fashion, whereas secondary PH lesions develop via polyclonal expansion of endothelial cells

Figure 1

Dendrogram showing the relatedness of gene expression profiles between normal lungs (N), sporadic primary pulmonary hypertension (PPH) lungs, and familial primary pulmonary hypertension (FPPH) lungs. Total RNA from the lung was assayed using Affymetrix HU FL arrays. GeneSpring® software was used to generate an experimental tree by *k*-tuple means analysis. The relatedness of each sample to one another is depicted by the dendrogram. Blue lines, normal samples; green lines, FPPH samples; and red lines, sporadic PPH. The degree of relatedness is proportional to the length of the lines. Yellow lines, The PPH samples originate from a different phylogeny to the six normal samples or the three FPPH samples, which originate as depicted from the black lines. FPPH refers to a patient whose family history could not be determined, but whose expression pattern suggests a familial form. The black box surrounds a group of genes that appear to be differentially expressed between sporadic PPH and all other samples, and might represent discriminating genes for this condition.

[26,27]. The finding of monoclonal growth implies that, as in neoplasia, genetic mutations may occur which provide a selective growth advantage for a single endothelial cell. The TGF- β family of signaling molecules inhibits the proliferation of endothelial cells by modulating proteins involved in cell cycle control and angiogenesis [23]. Mutations in TGF- β signaling molecules have been implicated in initiation and progression of cancers and atherosclerotic plaques, because insertions or deletions within a 10-adenine microsatellite region in exon 3 of the TGF- β RII gene have been demonstrated [28,29]. An 8-guanine region within exon 3 of Bax, a proapoptotic member of the Bcl-2 gene family, is similarly prone to instability [30].

To investigate whether cells within plexiform lesions exhibit microsatellite instability and mutations in TGF- β signaling genes, Yeager *et al* performed microdissection of plexiform lesions from patients with sporadic PPH and those with secondary forms of PH [31]. The results showed that: first, the endothelial cells within PPH lesions are genetically unstable, with 50% of lesions demonstrating microsatellite instability; second,

one-third of the lesions from PPH show mutation of at least one allele of TGF- β RII, but none of the secondary PH or normal lungs display mutations; and, finally, 21% percent of lesions in PPH show Bax mutations, whereas none of the secondary PH or normals show this mutation. Furthermore, we have performed mutational analysis of the microdissected plexiform lesions from five patients with FPPH. In total, 22 lesions from 5 patients were analyzed for mutations of TGF- β RII and Bax. We report here that none of the 22 lesions examined showed mutations of TGF- β RII or Bax, in contrast to the lesions of patients with spontaneous PPH. In summary, the monoclonal expansion of endothelial cells seen in sporadic PPH may result from mutations in regulatory genes such as TGF- β RII and Bax.

Expression analysis of human PPH

Gene microarray technology [32] now permits the analysis of the gene expression profile of lung tissue obtained from patients with primary PH to compare with that found in normal lung tissue. Because the vascular lesions are homogeneously distributed throughout the entire lung, a tissue fragment of the lung is probably representative of the whole lung. RNA extracted from such fragments is likely to provide meaningful information regarding the changes in gene expression pattern in PPH when compared with structurally normal lung tissue. We can model the range of normality by examining a sufficient number of lung tissue samples. Methods exist for determining coordination in expression data using cluster expression profiles. Cluster analysis can give clues to the pathogenesis by displaying genes whose expression is altered in a coordinate manner. Finally, an important goal is to discern sets of genes that differentiate between normal and disease states – or discrimination analysis. Building discrimination models has a long history in statistical pattern recognition and machine learning, and has been applied to cancer paradigms using gene expression data [33]. For our study, we used Affymetrix oligonucleotide microarrays (human FL) to characterize the expression pattern in the lung tissue obtained from six patients with PPH, including two patients with FPPH, and from six patients with histologically normal lungs [34].

Although the number of patient samples was small, gene dendrogram, cluster analysis and concordant expression differences show that there are categorical and robust differences in the profile of expressed genes between structurally normal lungs, lungs from patients with sporadic PPH, and lungs from patients with FPPH. We began our study of differential gene expression in PPH with the assumption that sporadic PPH is a disease with typical and dramatic histological features, which are sufficiently distinct from the structurally normal lung but essentially indistinguishable from those features found in FPPH lungs. We found that only 307 genes were significantly different in their expression when PH tissues were com-

pared with structurally normal lung tissues. Genes encoding ribosomal, mitochondrial and cytoskeletal proteins and genes encoding ion channels and enzymes were differentially expressed between PH and normal lungs. Several transcription factor genes and genes related to cyclin-dependent kinases were different in their expression, indicating that the PH gene signature reflects a profound imbalance in the control of genes involved in cell proliferation and apoptosis. Furthermore, as shown in Figure 1, whole-tissue total RNA expression profiles demonstrate striking differences in the expression signatures between sporadic and familial PPH. Importantly, the differences in expression profiles are complemented by independent gene mutation analysis. Only the plexiform lesions in the lungs from patients with sporadic PPH [31], not those lesions in FPPH lungs, display mutations of the Bax and TGF- β RII genes. It is possible that these mutational differences may lead to gene expression changes. The RNA expression data and the DNA mutation data taken together [31] lead to the conclusion that sporadic and familial PPH are mechanistically distinct. In summary, microarray gene expression analysis and profiling is a useful molecular tool that provides a better characterization and understanding of the pathobiology of distinct clinical phenotypes of PH.

Conclusions

Genomic approaches to the investigation of PH in animals or relevant tissues have vastly expanded our knowledge about the pathobiology of pulmonary hypertensive diseases. Human genetic analysis will undoubtedly expand and discover further gene mutations involved in the pathogenesis of PH. Gene expression profiling of different animal models of PH, and comparison of these profiles with human PH, will assist in determining the complex pathways that comprise the response that we term 'pulmonary hypertensive tissue remodeling'.

Acknowledgements

This work was supported by the NHLBI Grant HL60913-01 and by a grant from the Kinner-Wisham Family Foundation. The authors wish to thank James Campbell for supporting the establishment of the UCHSC Microarray Facility. The gene expression analysis was performed at the University of Colorado Comprehensive Cancer Center Gene Expression Core Facility.

References

1. Rich S: **Executive summary from the World Symposium on primary pulmonary hypertension 1998.** [www.who.int/ncd/cvd/pph.html].
2. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA: **Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.** *Am J Hum Genet* 2000, **67**:737-744.
3. The International PPH Consortium, Lane KB, Machado RD, Pauculo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC: **Heterozygous germline mutations in *BMPR2*, encoding a TGF- β receptor, cause familial primary pulmonary hypertension.** *Nat Genet* 2000, **26**:81-84.
4. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE: **An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.** *N Engl J Med* 1992, **327**:70-75.
5. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: **Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.** *N Engl J Med* 1993, **328**:1732-1739.
6. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF: **5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension.** *Am J Respir Crit Care Med* 1998, **157**:219-229.
7. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF: **Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.** *Am J Respir Crit Care Med* 1999, **159**:1925-1932.
8. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM: **Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.** *Am J Pathol* 1999, **155**:411-419.
9. Voelkel NF, Tuder RM, Wade K, Hoper M, Lepley RA, Goulet JL, Koller BH, Fitzpatrick F: **Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats.** *J Clin Invest* 1996, **97**:2491-2498.
10. Fagan KA, Fouty BW, Tyler RC, Morris KG Jr, Hepler LK, Sato K, LeCras TD, Abman SH, Weinberger HD, Huang PL, McMurtry IF, Rodman DM: **The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia.** *J Clin Invest* 1999, **103**:291-299.
11. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S, Geraci MW: **Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling.** *Am J Respir Crit Care Med* 2001, in press.
12. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, Voelkel NF: **Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension.** *J Clin Invest* 1999, **103**:1509-1515.
13. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M: **Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor.** *Nat Med* 2000, **6**:698-702.
14. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon GG, Waltenberger J, Voelkel NF, Tuder RM: **Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.** *FASEB J* 2001, **15**:427-438.
15. Janssens SP, Bloch KD, Nong Z, Gerard RD, Zoldhelyi P, Collen D: **Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats.** *J Clin Invest* 1996, **98**:317-324.
16. Geraci M, Gao B, Shepherd D, Allard J, Curiel D, Westcott J, Voelkel N: **Pulmonary prostacyclin synthase overexpression by adenovirus transfection and in transgenic mice [abstract].** *Chest* 1998, **114**:99S.
17. Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, Miyatake K, Kaneda Y, Tanabe T: **Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats.** *Circulation* 2000, **102**:2005-2010.
18. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN: **Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.** *Proc Natl Acad Sci USA* 2000, **97**:13275-13280.
19. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA III, Newman JH: **Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension.** *Am J Respir Crit Care Med* 1995, **152**:93-97.
20. O'Donovan MC, Oefner PJ, Roberts SC, Austin J, Hoogendoorn B, Guy C, Speight G, Upadhyaya M, Sommer SS, McGuffin P: **Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection.** *Genomics* 1998, **52**:44-49.

21. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC: **Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF- β family.** *J Med Genet* 2000, **37**: 741–745.
22. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA 3rd, Newman J, Williams D, Galie N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert M, Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC: **BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.** *Am J Hum Genet* 2001, **68**:92–102.
23. Massague J, Blain SW, Lo RS: **TGF- β signaling in growth control, cancer, and heritable disorders.** *Cell* 2000, **103**: 295–309.
24. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J: **Endoglin, a TGF- β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1.** *Nat Genet* 1994, **8**:345–351.
25. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA: **Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.** *Nat Genet* 1996, **13**:189–195.
26. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tudor RM: **Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.** *J Clin Invest* 1998, **101**:927–934.
27. Tudor RM, Radisavljevic Z, Shroyer KR, Polak JM, Voelkel NF: **Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension.** *Am J Respir Crit Care Med* 1998, **158**:1999–2001.
28. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B: **Inactivation of the type II TGF- β receptor in colon cancer cells with microsatellite instability.** *Science* 1995, **268**:1336–1338.
29. McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, Weksler BB, Sanborn TA, Bergman G, Bush HL: **Genomic instability in the type II TGF- β 1 receptor gene in atherosclerotic and restenotic vascular cells.** *J Clin Invest* 1997, **100**: 2182–2188.
30. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M: **Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.** *Science* 1997, **275**:967–969.
31. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tudor RM: **Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension.** *Circ Res* 2001, **88**:E2–E11.
32. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL: **Expression monitoring by hybridization to high-density oligonucleotide arrays.** *Nat Biotechnol* 1996, **14**:1675–1680.
33. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES: **Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.** *Science* 1999, **286**:531–537.
34. Geraci MW, Moore MD, Gesell TL, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tudor RM, Voelkel NF: **Gene expression patterns in the lungs of patients with primary pulmonary hypertension – a gene microarray analysis.** *Circ Res* 2001, **88**: 555–562.